Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

Summary

To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF)

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications